Sino Biopharmaceutical Limited: Carcinoma, Non-Small-Cell Lung trials

The registry lists 29 Carcinoma, Non-Small-Cell Lung studies with Sino Biopharmaceutical Limited as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 1 9Phase 2 15Phase 3 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsRecruitingNCT07371663Phase 1/2
• FHND9041 Versus Afatinib for Non-small Cell Lung CancerEnrolling by invitationNCT06759857Phase 3
• Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung CancersNot yet recruitingNCT06585059Phase 1
• A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruitingNCT06496490Phase 2
• D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Phase 3
• Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.RecruitingNCT05922345Phase 3
• A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Phase 2
• TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Not yet recruitingNCT05718167Phase 3
• A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsTerminatedNCT06507891Phase 1/2
• To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.Status unknownNCT05859373Phase 1/2
• Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male VolunteersCompletedNCT05800418Phase 1
• A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).Status unknownNCT05346952Phase 3
• TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Phase 1/2
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Status unknownNCT04964479Phase 3
• A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Phase 3
• A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerStatus unknownNCT04398940Phase 2
• A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone MetastasisStatus unknownNCT04325776Phase 2
• A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Phase 3
• A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT04306926Phase 2
• A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsStatus unknownNCT04273815Phase 1/2
• Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung CancerStatus unknownNCT04073537Phase 3
• Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibStatus unknownNCT04056572Phase 2
• Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT04009317Phase 3
• Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03972189Phase 2
• Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）Status unknownNCT03910127Phase 1
• A Phase I Study of TQ-B3456 on Tolerance and PharmacokineticsTerminatedNCT03754244Phase 1
• Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）CompletedNCT02388919Phase 2/3
• To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT02029209Phase 2/3
• Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）CompletedNCT01924195Phase 2